Market Place
Sourcing Support
Juvisé Acquires Multiple Sclerosis Drug PONVORY and also Opens Its Capital
26 Mar 2024 //
BUSINESSWIRE
Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY
25 Jan 2024 //
PR NEWSWIRE
J&J unloads certain Ponvory rights to Vanda for $100M
08 Dec 2023 //
FIERCE PHARMA
Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY
07 Dec 2023 //
PR NEWSWIRE
NICE recommends PONVORY for treatment of relapsing forms of multiple sclerosis
04 Jan 2022 //
PHARMAFILE
SMC accepts oral therapy for relapsing multiple sclerosis
10 Nov 2021 //
PHARMATIMES
Subgroup Analysis: Benefits of PONVORYTM over teriflunomide in Phase 3 Study
13 Oct 2021 //
BUSINESSWIRE
Janssen’s MS treatment Ponvory is granted UK marketing authorisation
11 Aug 2021 //
PHARMA FILE
Janssen’s MS treatment Ponvory is granted UK marketing authorisation
11 Aug 2021 //
PHARMA FILE
European Commission approves PONVORYTM ? (ponesimod)
24 May 2021 //
BUSINESSWIRE
Janssen Receives Positive CHMP Opinion for PONVORY™ ? (ponesimod)
29 Mar 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.